somatropin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Infant, Small for Gestational Age

Conditions

Infant, Small for Gestational Age

Trial Timeline

Dec 1, 2002 → Jun 1, 2007

NCT ID

NCT00191529

About somatropin

somatropin is a phase 3 stage product being developed by Eli Lilly for Infant, Small for Gestational Age. The current trial status is completed. This product is registered under clinical trial identifier NCT00191529. Target conditions include Infant, Small for Gestational Age.

What happened to similar drugs?

4 of 13 similar drugs in Infant, Small for Gestational Age were approved

Approved (4) Terminated (4) Active (8)

✅Placebo + CisaprideJohnson & JohnsonApproved

✅alglucosidase alfa + alglucosidase alfaSanofiApproved

✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved

✅VigabatrinLundbeckApproved

🔄RotaTeq (V260) + IPVMerckPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

🔄Genotropin (PN-180,307) Somatropin + Control-no treatmentPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00191360	Phase 3	Completed	Jan 1, 2003	May 1, 2006	Adult Growth Hormone Deficiency
NCT00191529	Phase 3	Completed	Dec 1, 2002	Jun 1, 2007	Infant, Small for Gestational Age
NCT00406926	Phase 3	Completed	Aug 1, 1999	Aug 1, 2003	Turner Syndrome
NCT00490191	Approved	Completed	Jan 1, 1999	Jul 1, 2001	Hypopituitarism

Competing Products

20 competing products in Infant, Small for Gestational Age

See all competitors

Product	Company	Stage	Hype Score
SPIKEVAX	Moderna	Preclinical	0
TSHA-101	Taysha Gene Therapies	Phase 1/2	30
Placebo + Cisapride	Johnson & Johnson	Approved	35
RotaTeq (V260) + IPV	Merck	Phase 3	40
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
MAS825 + Placebo	Novartis	Phase 2	39
epoetin beta + epoetin beta	Roche	Pre-clinical	26
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
Prevenar (13v)	Pfizer	Pre-clinical	26
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV	Sanofi	Phase 3	40
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Myozyme	Sanofi	Phase 2	35
Bacillus Clausii Multi ATB Resist + Placebo	Sanofi	Approved	43
Radiprodil	UCB	Phase 2	27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care	Bayer	Pre-clinical	23
Sabril®	Lundbeck	Pre-clinical	23
Vigabatrin	Lundbeck	Approved	32